(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 19.2% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.15%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.21%.
Ironwood Pharmaceuticals's revenue in 2026 is $296,151,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $76,273,788,475, with the lowest IRWD revenue forecast at $72,223,419,906, and the highest IRWD revenue forecast at $79,391,463,477. On average, 6 Wall Street analysts forecast IRWD's revenue for 2027 to be $79,621,375,703, with the lowest IRWD revenue forecast at $74,625,268,901, and the highest IRWD revenue forecast at $84,151,135,721.
In 2028, IRWD is forecast to generate $81,501,438,086 in revenue, with the lowest revenue forecast at $75,584,051,799 and the highest revenue forecast at $88,362,932,024.